Tyra Biosciences Advances BEACH301 Dose Escalation

Tyra Bioscience, Inc (TYRA) announced an update on their ongoing clinical study.

Tyra Biosciences’ BEACH301 trial, officially titled “A Multicenter, Phase 2, Dose-Escalation/Dose-Expansion Study of TYRA-300 in Children With Achondroplasia With Open Growth Plates,” is built to gauge safety, tolerability, and dose guidance for the oral FGFR3 inhibitor in a rare pediatric growth disorder.

The intervention is TYRA-300, a once-daily sprinkle capsule/mini-tablet dosed by body weight across four escalating cohorts ranging from 0.125 to 0.50 mg/kg, aiming to normalize overactive FGFR3 signaling and stimulate growth.

This is a non-randomized, sequential dose-escalation study with open-label assessment, no masking, and a treatment-focused primary goal, allowing investigators to observe dose responses directly while moving patients through predefined cohorts.

The study began after the January 29, 2025 submission, targets primary readout aligned with the Phase 2 dosing schedule, estimates overall completion following dose expansion, and most recently posted an update on February 2, 2026, signaling active recruitment momentum.

For investors, the update underscores TYRA-300 as a differentiated entrant in the achondroplasia race, where BioMarin’s Voxzogo currently dominates; steady progress here could re-rate TYRA shares on potential partnership or expedited pediatric milestones, though any safety hiccup would amplify volatility across rare-disease peers.

Study remains open with further details available on the ClinicalTrials portal.

To learn more about TYRA’s potential, visit the Tyra Bioscience, Inc drug pipeline page.